The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease
出版年份 2021 全文链接
标题
The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease
作者
关键词
-
出版物
Frontiers in Oncology
Volume 11, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-02-22
DOI
10.3389/fonc.2021.625872
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation
- (2020) Huaxia Yang et al. CLINICAL IMMUNOLOGY
- Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis
- (2020) Elizaveta Efuni et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
- (2020) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis
- (2020) Mitchell S von Itzstein et al. CLINICAL CHEMISTRY
- Moving towards personalized treatments of immune-related adverse events
- (2020) Khashayar Esfahani et al. Nature Reviews Clinical Oncology
- Immune-related adverse events of checkpoint inhibitors
- (2020) Manuel Ramos-Casals et al. Nature Reviews Disease Primers
- Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study
- (2020) Nieves Martinez Chanza et al. Journal for ImmunoTherapy of Cancer
- Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
- (2020) J. Haanen et al. ANNALS OF ONCOLOGY
- Use of Immune Checkpoint Inhibitors in Patients With Pre-established Inflammatory Bowel Diseases: Retrospective Case Series
- (2020) Manuel B. Braga Neto et al. Clinical Gastroenterology and Hepatology
- Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies
- (2020) Wenhui Xie et al. AUTOIMMUNITY REVIEWS
- Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
- (2020) Yohann Loriot et al. EUROPEAN JOURNAL OF CANCER
- Improving safety of cancer immunotherapy via delivery technology
- (2020) Doudou Hu et al. BIOMATERIALS
- Clinical Outcomes of Patients with Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated with Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study
- (2019) Alessio Cortellini et al. ONCOLOGIST
- Safety and efficacy of PD-1 inhibitors in non–small cell lung cancer patients positive for antinuclear antibodies
- (2019) Yasuto Yoneshima et al. LUNG CANCER
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer
- (2019) Fiamma Berner et al. JAMA Oncology
- Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors
- (2019) Laura C. Kennedy et al. Journal of the National Comprehensive Cancer Network
- Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications
- (2019) Biagio Ricciuti et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors
- (2019) Fausto Petrelli et al. JOURNAL OF IMMUNOTHERAPY
- Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study
- (2019) Alice Tison et al. Arthritis & Rheumatology
- Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
- (2019) Aneet Kaur et al. MEDICINE
- Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities
- (2019) Salahaldin A. Tahir et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
- (2019) Hamzah Abu-Sbeih et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease
- (2018) Noha Abdel-Wahab et al. ANNALS OF INTERNAL MEDICINE
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2018) J B A G Haanen et al. ANNALS OF ONCOLOGY
- Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
- (2018) Katharina C. Kähler et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Clinicopathological value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression in synovium of patients with rheumatoid arthritis
- (2018) Kotaro Matsuda et al. CLINICAL AND EXPERIMENTAL MEDICINE
- Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
- (2018) François-Xavier Danlos et al. EUROPEAN JOURNAL OF CANCER
- PD-1 deficiency augments bone marrow failure in a minor-histocompatibility antigen mismatch lymphocyte infusion model
- (2018) Maile K. Hollinger et al. EXPERIMENTAL HEMATOLOGY
- Immune checkpoint blockade therapy
- (2018) Thomas Wieder et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders
- (2018) Giulia C. Leonardi et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer-associated Dermatomyositis: Does the PD-1 Checkpoint Pathway Play a Role?
- (2018) MOISES LABRADOR-HORRILLO et al. JOURNAL OF RHEUMATOLOGY
- Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors
- (2018) Michael F. Gowen et al. Journal of Translational Medicine
- Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience
- (2018) Michael D. Richter et al. Arthritis & Rheumatology
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer
- (2018) Kathryn C. Arbour et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
- (2017) Ralf Gutzmer et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- PD-1 hi CXCR5 − CD4 + T FH Cells Play Defense in Cancer and Offense in Arthritis
- (2017) Chunyan Gu-Trantien et al. TRENDS IN IMMUNOLOGY
- Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
- (2017) Chipman RG Stroud et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Prediction and Prevention of Autoimmune Disease in the 21st Century: A Review and Preview
- (2016) Noel R. Rose AMERICAN JOURNAL OF EPIDEMIOLOGY
- Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade
- (2016) Patrizio Caturegli et al. AMERICAN JOURNAL OF PATHOLOGY
- The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma
- (2016) B. Lee et al. ANNALS OF ONCOLOGY
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
- (2016) A. M. Menzies et al. ANNALS OF ONCOLOGY
- PD-1/PD-L and autoimmunity: A growing relationship
- (2016) Mohammad Reza Zamani et al. CELLULAR IMMUNOLOGY
- Co-stimulatory and Co-inhibitory Pathways in Autoimmunity
- (2016) Qianxia Zhang et al. IMMUNITY
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
- (2016) Katrin Klocke et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Exacerbation of Autoimmune Thyroiditis by CTLA-4 Blockade: A Role for IFNγ-Induced Indoleamine 2, 3-Dioxygenase
- (2016) Rajni Sharma et al. THYROID
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- (2016) Douglas B. Johnson et al. JAMA Oncology
- Prevalence of Autoimmune Disease Among Patients With Lung Cancer
- (2016) Saad A. Khan et al. JAMA Oncology
- Systemic lupus erythematosus and malignancies risk
- (2015) Song Mao et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis
- (2014) Bianca van den Berg et al. Nature Reviews Neurology
- Autoimmune encephalitis update
- (2014) J. Dalmau et al. NEURO-ONCOLOGY
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- Primary Sjögren's syndrome and malignancy risk: a systematic review and meta-analysis
- (2013) Yan Liang et al. ANNALS OF THE RHEUMATIC DISEASES
- Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo
- (2012) J. Gotot et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy
- (2011) Meleeneh Kazarian et al. Molecular Cancer
- Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
- (2008) Brian T. Fife et al. IMMUNOLOGICAL REVIEWS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search